Pfizer announced today that the European Commission (EC) has approved its trastuzumab biosimilar, Trazimera, referencing Herceptin, for marketing. The approval makes Trazimera the fourth trastuzumab biosimilar (following Kanjinti, Ontruzant, and Herzuma) to be approved by the EC, and the first approval of an anticancer biosimilar for Pfizer.
Pfizer announced today that the European Commission (EC) has approved its trastuzumab biosimilar, Trazimera, referencing Herceptin, for marketing. The approval makes Trazimera the fourth trastuzumab biosimilar (following Kanjinti, Ontruzant, and Herzuma) to be approved by the EC, and the first approval of an anticancer biosimilar for Pfizer.
Today’s approval allows the drug to be marketed in the 28 member states of the European Union as well as in the European Economic Area. The biosimilar has been approved to treat HER2-positive breast cancer, metastatic gastric cancer, and gastroesophageal junction adenocarcinoma, the same indications as its reference product.
In a statement, Diana Lüftner, Dr med, of the Charité Campus Benjamin Franklin in Berlin, Germany, and member of the presidency of the German Society of Hematology and Medical Oncology, hailed the approval, saying that the biosimilar “has the potential to help many patients with HER2-overexpressing cancers, such as breast and gastric, which can correlate with poor outcomes and aggressive disease. Today’s approval will help enable greater access for patients and physicians across Europe, without compromising on quality, efficacy and safety.”
The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in June 2018, which relied on a data package that included results from Pfizer’s phase 3 REFLECTIONS B327-02 study, results of which were presented at the European Society for Medical Oncology conference in 2017. The study, in 707 patients with HER2-positive metastatic breast cancer, found that Pfizer’s biosimilar was similar to EU-licensed trastuzumab in terms of efficacy, safety, immunogenicity, and pharmacokinetics when used as first-line treatment.
While Pfizer has cleared the final regulatory hurdle for its product in the European market, in April 2018, Pfizer received a Complete Response Letter from the FDA for the same molecule. The company says that the FDA highlighted the need for “additional technical information,” and that the agency did not request information related to safety or clinical data submitted in the Biologics License Application. Pfizer indicated that it will work closely with the FDA to address the letter’s contents and that it remains committed to developing the product.
In the United States, only 1 trastuzumab biosimilar, Mylan and Biocon’s Ogivri, has received approval from the FDA. No launch date has been announced for the drug.
BioRationality: Calling on Developers to Help Address Remaining Biosimilar Issues
October 3rd 2023Sarfaraz K. Niazi, PhD, summarized the citizen petitions he's filed to the FDA as well as changes he believes are needed to propel the biosimilar industry into the future, including calling on biosimilar manufacturers to help.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
EC Approves First MS Biosimilar; Coherus Receives CRL for Neulasta Onpro Competitor
September 27th 2023With the European Commission's (EC) approval of Tyruko, Europe receives its first natalizumab biosimilar and first biosimilar to treat multiple sclerosis (MS), while Coherus Biosciences received a complete response letter (CRL) for its biosimilar for Neulasta Onpro.
2 Clarke Drive
Cranbury, NJ 08512